<DOC>
	<DOC>NCT02090465</DOC>
	<brief_summary>Assessment of treatment success and quality of life in patients with actinic keratoses under therapy with Ingenol Mebutate (Picato) in a period of 8 weeks.</brief_summary>
	<brief_title>Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks</brief_title>
	<detailed_description>Non-interventional (observational) study (NIS), non-controlled, prospective cohort study.</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>• Nonhyperkeratotic, nonhypertrophic actinic keratoses where treatment with Picato® is indicated and the treatment is intended by physicians. Preceding use of Picato® on the area planned for treatment Any other specific local treatment of actinic keratoses on the area planned for treatment during the last 8 weeks Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment Open wounds on the area planned for treatment Contraindications according to prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Actinic Keratosis</keyword>
</DOC>